

NEKTAR THERAPEUTICS  
Form 8-K  
March 30, 2004

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **March 30, 2004**

**Nektar Therapeutics**

(Exact Name of Registrant as Specified in Charter)

**Delaware**

(State or Other Jurisdiction of Incorporation)

**000-23556**

(Commission File No.)

**94-3134940**

(IRS Employer Identification No.)

**150 Industrial Road  
San Carlos, CA 94070**

(Address of Principal Executive Offices and Zip Code)

Registrant's telephone number, including area code: **(650) 631-3100**

---



**Item 5. Other Events and Regulation FD Disclosure.**

On March 30, 2004, Nektar Therapeutics issued a press release entitled Nektar Therapeutics Announces Completion of Redemption of 3% Convertible Subordinated Notes due June 2010. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.**

Number	Description
99.1	Press Release, dated March 30, 2004, entitled Nektar Therapeutics Announces Completion of Redemption of 3% Convertible Subordinated Notes due June 2010

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**NEKTAR THERAPEUTICS**

Dated: March 30, 2004

By: */s/ Ajit S. Gill*  
Ajit S. Gill  
President, Chief Executive Officer and  
Director

Exhibit Index

<b>Number</b>	<b>Description</b>
99.1	Press Release, dated March 30, 2004, entitled Nektar Therapeutics Announces Completion of Redemption of 3% Convertible Subordinated Notes due June 2010